Tag: Astrazeneca
AstraZeneca buys American biotech Icosavax, vaccine specialist
(AOF) – AstraZeneca today announced the successful completion of the acquisition of Icosavax, a US clinical-stage biopharmaceutical company focused on the development of high-potential differentiated vaccines using an innovative virus-like…
AstraZeneca: ‘major breakthrough’ in lung cancer
(CercleFinance.com) – AstraZeneca reports that the results of a phase III trial showed that Tagrisso (osimertinib) provided a ‘statistically and clinically significant’ improvement in progression-free survival (PFS) in patients with…
AstraZeneca: FDA approves Tagrisso against lung cancer – 02/19/2024 at 11:06
(AOF) – AstraZeneca announces that its product Tagrisso (osimertinib) combined with chemotherapy has been approved in the United States for the treatment of adult patients with locally advanced or metastatic…
AstraZeneca: New decline after two negative analyzes
(CercleFinance.com) – The stock is down almost 2% today on the London Stock Exchange after two negative analyses. UBS confirms its sell advice on the stock with a target lowered…
AstraZeneca forecasts an increase in its results in 2024
Published on 02/08/2024 at 08:44 a.m. Feb 8 (Reuters) – AstraZeneca said on Thursday it expects revenue and profit to rise in 2024,…
AstraZeneca: positive trial in cardiac amyloidosis
(CercleFinance.com) – AstraZeneca announces that the results of a phase III trial carried out in Japan of acoramide in adults with transthyretin cardiac amyloidosis (ATTR-CM) are consistent with those of…
AstraZeneca: encouraging results in liver cancer
(CercleFinance.com) – AstraZeneca announces that positive results from a phase III trial showed that Imfinzi (durvalumab) combined with TACE (a chemoembolization that blocks the hepatic artery to treat liver cancer…
AstraZeneca: Jefferies downgrades to ‘keep’
(CercleFinance.com) – Jefferies announced on Wednesday that it had lowered its recommendation on AstraZeneca shares from ‘buy’ to ‘hold’ with a price target reduced from 12,500 to 11,000 pence. In…
AstraZeneca: acquisition of Gracell welcomed by UBS
(CercleFinance.com) – UBS reaffirms its ‘buy’ recommendation on AstraZeneca with a price target maintained at 13,000 pence, representing a potential increase of 25% for the stock, welcoming the acquisition of…
AstraZeneca: approval of Beyfortus in China
(CercleFinance.com) – AstraZeneca announces that Beyfortus (nirsevimab), developed with Sanofi, has been approved in China for the prevention of lower respiratory tract infection (LRTI) by respiratory syncytial virus (RSV) in…
AstraZeneca: green light from the FDA in rare neuropathy
(CercleFinance.com) – The American drug authority, the Food and Drug Administration (FDA), has approved a drug developed by AstraZeneca and its partner Ionis against a rare neuropathic disease likely to…
AstraZeneca and Sanofi to supply 230,000 additional RSV vaccines for infants to the US market – 12/14/2023 at 10:38 p.m.
(Adds details from Sanofi in paragraphs 2, 9 and 10) by Trevor Hunnicutt and Michael Erman Makers of a respiratory syncytial virus (RSV) vaccine for infants, whose supply is limited,…